The Food and Drug Administration said it approved Kura Oncology’s (KURA) Komzifti,, a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology trading halted, news pending
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology Advances Precision Cancer Therapies
- Kura Oncology’s Positive Outlook in Latest Earnings Call
- Kura Oncology’s Promising Market Position and Anticipated Approval of Ziftomenib Boosts Buy Rating